PDGF-BB Equine
Escherichia Coli.
Glioma-derived growth factor, GDGF, Osteosarcoma-derived Growth Factor, ODGF, SIS, SSV, PDGF2, c-sis, FLJ12858, PDGF-BB, PDGF B-chain, Platelet-derived growth factor beta polypeptide, Becaplermin.
Description
PDGF-BB Equine Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide dimer chain containing 2 x 110 amino acids and having a total molecular mass of 24.8kDa.
The PDGF-BB is purified by proprietary chromatographic techniques.
Product Specs
Glioma-derived growth factor, GDGF, Osteosarcoma-derived Growth Factor, ODGF, SIS, SSV, PDGF2, c-sis, FLJ12858, PDGF-BB, PDGF B-chain, Platelet-derived growth factor beta polypeptide, Becaplermin.
Escherichia Coli.
MSLGSLAVAE PAMIAECKTR TEVFEISRRL IDRTNANFLV WPPCVEVQRC SGCCNNRHVQ CRPTQVQLRP VQVRKIEIVR KKPTFKKATV TLEDHLACKC ETVGAARPVT
Product Science Overview
Platelet-Derived Growth Factor (PDGF) is a significant growth factor involved in various cellular processes, including cell proliferation, differentiation, and angiogenesis. Among its different isoforms, PDGF-BB is particularly notable for its role in wound healing and tissue repair. The recombinant form of PDGF-BB, specifically derived from equine sources, has garnered attention for its potential applications in veterinary medicine and research.
PDGF-BB is a homodimeric protein composed of two B chains linked by disulfide bonds. It is synthesized as a prepro-protein that undergoes intracellular processing to become active . The mature PDGF-BB protein plays a crucial role in stimulating the proliferation and migration of mesenchymal cells, which are essential for tissue repair and regeneration .
Recombinant equine PDGF-BB is produced using E. coli expression systems. The gene encoding the equine PDGF-BB is inserted into the bacterial cells, which then produce the protein. The recombinant protein is subsequently purified to achieve high levels of purity, typically greater than 95% as determined by SDS-PAGE . This high purity is essential for ensuring the protein’s efficacy and safety in various applications.
Recombinant equine PDGF-BB has shown promise in several veterinary applications, particularly in the treatment of equine injuries. It has been used to enhance the healing of tendon and ligament injuries, which are common in horses. The growth factor promotes the proliferation of fibroblasts and other cells involved in the repair process, thereby accelerating healing and improving outcomes .
The primary mechanism by which PDGF-BB exerts its effects is through binding to its receptors on the surface of target cells. This binding activates intracellular signaling pathways that lead to cell proliferation, migration, and survival. Additionally, PDGF-BB acts as a chemoattractant, drawing cells to the site of injury and promoting the formation of new blood vessels, which are crucial for tissue repair .
Ongoing research is exploring the broader applications of recombinant equine PDGF-BB in veterinary and human medicine. Studies are investigating its potential in bone regeneration, wound healing, and even in the treatment of certain degenerative diseases. The ability to produce recombinant PDGF-BB in large quantities and with high purity opens up new possibilities for its use in various therapeutic contexts .
